Search results
Results from the WOW.Com Content Network
No new suspicious 18F-FDG avid lesions. If progression by RECIST must verify with follow up; Partial metabolic response (PMR) Reduction of a minimum of 30% in target measurable tumor 18F-FDG SUL peak, with absolute drop in SUL of at least 0.8 SUL units. No increase >30% of SUL or size in all other lesions; No new lesions; Stable metabolic ...
Progressive disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Evaluation of non-target lesions. Complete response (CR): Disappearance of all non-target lesions and normalization of tumor marker level
Pancreatic islet cell tumors are today the major cause of death in persons with MEN-1. Tumors occur in 60-80% of persons with MEN-1 and they are usually multicentric. Multiple adenomas or diffuse islet cell hyperplasia commonly occurs. About 30% of tumors are malignant and have local or distant metastases. [5]
Multiple endocrine neoplasia (abbreviated MEN) is a condition which encompasses several distinct syndromes featuring tumors of endocrine glands, each with its own characteristic pattern. In some cases, the tumors are malignant, in others, benign. Benign or malignant tumors of nonendocrine tissues occur as components of some of these tumor ...
Multiple endocrine neoplasia type 2B (MEN 2B) is a genetic disease that causes multiple tumors on the mouth, eyes, and endocrine glands. It is the most severe type of multiple endocrine neoplasia , [ 2 ] differentiated by the presence of benign oral and submucosal tumors in addition to endocrine malignancies.
They may appear as either non-caseating or solidly caseating lesions. [20] Initially, tuberculomas appear hypodense on computed tomography (CT) scans with significant surrounding edema. [23] [3] The "target sign" is pathognomonic for tuberculoma on CT, with a nodular ring-enhancing mass and central calcification.
Epithelioid sarcoma is a slow-growing and relatively painless tumor, often resulting in a lengthy period of time between presentation and diagnosis. [8] Due to the difficulty of discerning this cancer as different from more common cancers, such as cancers of the skin (squamous cell carcinoma or basal cell carcinoma), it is often misdiagnosed, mistaken as a persistent wart or cyst.
While uncommon in solid tumors, chromosomal translocations are a common cause of these diseases. This commonly leads to a different approach in diagnosis and treatment of hematological malignancies. Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology.